Cardiac malformations
1 paper2 findings
Interventions
1SGLT2 inhibitors
no changein humans1RR 0.97
1 study
SGLT2 inhibitors
no changein humans1RR 0.97
SGLT2 inhibitors have no effect on cardiac malformations in humans (RR 0.97, 95% CI 0.64-1.48).
“SGLT2 inhibitor exposure was not associated with major congenital malformations (RR 0.94, 95% CI 0.68-1.29) or cardiac malformations (RR 0.97, 95% CI 0.64-1.48).”
ReviewEarly-pregnancy exposure in women with type 2 diabetes; insulin comparatorheartfemales
EndocrineOct 17, 2026
Associations
1SGLT2 inhibitors
upin humans1RR 2.79
1 study
SGLT2 inhibitors
upin humans1RR 2.79
SGLT2 inhibitors are associated with cardiac malformations in humans (RR 2.79, 95% CI 1.16-7.06).
“In a Korean cohort, exposure during gestational weeks 4-10 was associated with congenital heart defects (RR 2.79, 95% CI 1.16-7.06).”
ReviewExposure during gestational weeks 4-10 in a Korean cohort of women with type 2 diabetesheartfemales
EndocrineOct 17, 2026
Latest
1 in 12 monthsEndocrine
Periconceptional and early-pregnancy exposure to SGLT2 inhibitors and congenital malformations: a systematic review and meta-analysis
Meta-analysis of observational studiesPopulations
bioRxiv
TGFβ−induced embryonic cell senescence at the origin of the Cornelia de Lange syndrome
Preprint: experiments in miceCellular senescence